Free Trial
NASDAQ:CELU

Celularity (CELU) Stock Price, News & Analysis

Celularity logo
$0.61 -0.02 (-3.19%)
As of 02:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Celularity Stock (NASDAQ:CELU)

Advanced

Key Stats

Today's Range
$0.60
▼
$0.63
50-Day Range
$0.63
▼
$1.71
52-Week Range
$0.56
▼
$2.55
Volume
75,655 shs
Average Volume
1.24 million shs
Market Capitalization
$19.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Celularity is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease.

The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.

AI Generated. May Contain Errors.

Celularity Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

CELU MarketRank™: 
0.365853658535 of 5 stars

Celularity scored higher than 7% of companies evaluated by MarketBeat, and ranked 865th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Celularity has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Celularity has only been the subject of 1 research reports in the past 90 days.

  • Read more about Celularity's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Celularity is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Celularity is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    1.99% of the float of Celularity has been sold short.
  • Short Interest Ratio / Days to Cover

    Celularity has a short interest ratio ("days to cover") of 2.33, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Celularity has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Celularity does not currently pay a dividend.

  • Dividend Growth

    Celularity does not have a long track record of dividend growth.

  • News Sentiment

    Celularity has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Celularity this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Celularity insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.30% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    19.02% of the stock of Celularity is held by institutions.

  • Read more about Celularity's insider trading history.
Receive CELU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CELU Stock News Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
See More Headlines

CELU Stock Analysis - Frequently Asked Questions

Celularity's stock was trading at $1.11 at the start of the year. Since then, CELU shares have decreased by 45.6% and is now trading at $0.6040.

Celularity, Inc. (NASDAQ:CELU) posted its quarterly earnings data on Tuesday, October, 20th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $5.43 million for the quarter.

Celularity's stock reverse split on the morning of Thursday, February 29th 2024.The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Top institutional shareholders of Celularity include State Street Corp (0.18%).
View institutional ownership trends
.

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Recursion Pharmaceuticals (RXRX), Tesla (TSLA), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA) and Altimmune (ALT).

Company Calendar

Last Earnings
10/20/2026
Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CELU
CIK
1752828
Fax
N/A
Employees
115
Year Founded
2016

Profitability

EPS (Trailing Twelve Months)
($1.69)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$91.72 million
Net Margins
-246.65%
Pretax Margin
-245.66%
Return on Equity
N/A
Return on Assets
-48.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.11
Quick Ratio
0.10

Sales & Book Value

Annual Sales
$18.67 million
Price / Sales
1.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.32) per share
Price / Book
-0.46

Miscellaneous

Outstanding Shares
32,451,000
Free Float
15,284,000
Market Cap
$19.50 million
Optionable
Optionable
Beta
0.88

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:CELU) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners